Glycolic Acid → HCID 58614639, compound

HRID 923131Notes

Reaction equation

HRID 923131 reaction equation
[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([NH:8][C:9](=[O:23])[C:10]2[CH:15]=[CH:14][C:13]([N:16]3[CH2:21][CH2:20][NH:19][CH2:18][CH2:17]3)=[N:12][C:11]=2[CH3:22])=[CH:4][C:3]=1[C:24]1[CH:29]=[CH:28][CH:27]=[CH:26][N:25]=1.[C:30](O)(=[O:33])[CH2:31][OH:32]>>[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([NH:8][C:9](=[O:23])[C:10]2[CH:15]=[CH:14][C:13]([N:16]3[CH2:21][CH2:20][N:19]([C:31](=[O:32])[CH2:30][OH:33])[CH2:18][CH2:17]3)=[N:12][C:11]=2[CH3:22])=[CH:4][C:3]=1[C:24]1[CH:29]=[CH:28][CH:27]=[CH:26][N:25]=1

Participants

3

Reactant 2

HCID 757Glycolic AcidHCID 58614726HCID 58614726, compound

Product 1

HCID 58614639HCID 58614639, compound

Procedure

100 mg of N-(4-chloro-3-(pyridin-2-yl)phenyl)-2-methyl-6-(piperazin-1-yl)nicotinamide was coupled to glycolic acid via Procedure G. The product was purified on reverse phase HPLC to yield N-(4-chloro-3-(pyridin-2-yl)phenyl)-6-(4-(2-hydroxyacetyl)piperazin-1-yl)-2-methylnicotinamide. MS (Q1) 466.3 (M)+.

Workup

  1. customThe product was purified on reverse phase HPLC

Sources & evidence

ORD record
ord-fa20923b1ae84418934c21e0fd0b5304
Source dataset
uspto-grants-2016_03
Patent number
US09278961B2

Reaction notes

Loading…